Arch Biopartners Inc
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related … Read more
Arch Biopartners Inc (ACHFF) - Total Assets
Latest total assets as of June 2025: $266.46K USD
Based on the latest financial reports, Arch Biopartners Inc (ACHFF) holds total assets worth $266.46K USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Arch Biopartners Inc - Total Assets Trend (2014–2024)
This chart illustrates how Arch Biopartners Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Arch Biopartners Inc - Asset Composition Analysis
Current Asset Composition (September 2024)
Arch Biopartners Inc's total assets of $266.46K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.3% |
| Accounts Receivable | $724.67K | 77.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Arch Biopartners Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arch Biopartners Inc's current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 0.3% of total assets in 2024, down from 90.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 77.5% of total assets.
Arch Biopartners Inc Competitors by Total Assets
Key competitors of Arch Biopartners Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Arch Biopartners Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Arch Biopartners Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Arch Biopartners Inc is currently not profitable relative to its asset base.
Arch Biopartners Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.07 | 0.20 | 0.61 |
| Quick Ratio | 0.07 | 0.20 | 0.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.66 Million | $ -6.06 Million | $ -477.69K |
Arch Biopartners Inc - Advanced Valuation Insights
This section examines the relationship between Arch Biopartners Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 69.74 |
| Asset Growth Rate (YoY) | -20.1% |
| Total Assets | $935.62K |
| Market Capitalization | $65.25 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Arch Biopartners Inc's assets at a significant premium ( 69.74x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Arch Biopartners Inc's assets decreased by 20.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Arch Biopartners Inc (2014–2024)
The table below shows the annual total assets of Arch Biopartners Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-09-30 | $935.62K | -20.11% |
| 2023-09-30 | $1.17 Million | +88.40% |
| 2022-09-30 | $621.64K | -76.70% |
| 2021-09-30 | $2.67 Million | +259.94% |
| 2020-09-30 | $741.30K | +30.52% |
| 2019-09-30 | $567.98K | -15.57% |
| 2018-09-30 | $672.69K | +890.16% |
| 2017-09-30 | $67.94K | -70.08% |
| 2016-09-30 | $227.03K | -65.05% |
| 2015-09-30 | $649.50K | +60.06% |
| 2014-09-30 | $405.79K | -- |